Validating cdisc sdtm compliant submission ready clinical datasets radiochemical dating chemistry
This makes the process of mapping data into SDTM and ADa M datasets much more straightforward.
However, there are many legacy studies with valuable data that have not been conducted to this standard.
Nonetheless, given the magnitude and breadth of the requirements, companies should identify and address any capability gaps so that they are prepared to be fully compliant.
While it may be most expedient to focus on quick-fix solutions that address any immediate compliance needs, we believe that these latest regulations should motivate all sponsors to ensure that they have an up-to-date, comprehensive data standards strategy in place.
To correct this problem it often requires considerable mapping work which can be expensive.In December 2014, FDA released the finalized Guidance for Industry, “Providing Regulatory Submissions in Electronic Format—Standardized Study Data.” This guidance requires that studies that start after December 18, 2016, must incorporate certain data standards per the FDA Data Catalog.Of particular note are the FDA-approved versions of the CDISC Study Data Tabulation Model (SDTM v3.1.2) and Analysis Data Model (ADa M v.1.0) standards.While the FDA began accepting certain submissions electronically as early as 2003, and approved CDISC SDTM 1.0 as a data format for submission in 2004, the above regulations are notable in that they are binding.Thus, non-conformance may result in FDA refusal to review a submission (there is a very limited list of study types that can obtain waivers or exemptions).